Lead program, APG777, a novel subcutaneous half-life extended anti-IL-13 antibody, discovered by Paragon, enters first-in-human clinical trial
Apogee Therapeutics' recently announced upsized IPO further demonstrates the value of best-in-class antibodies for immunological and inflammatory disorders
https://finance.yahoo.com/news/paragon-therapeutics-recognizes-key-milestones-120000233.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.